Table II.
Formulation code | In vitro drug release | In vitro skin permeation | |||||||
---|---|---|---|---|---|---|---|---|---|
Zero-order kinetics (r 2) | First-order kinetics (r 2) | Higuchi kinetics (r 2) | Korsmeyer–Peppas kinetics | Zero-order kinetics (r 2) | Higuchi kinetics (r 2) | Korsmeyer–Peppas kinetics | |||
r 2 | n | r 2 | n | ||||||
F1 | 0.960 | 0.968 | 0.992 | 0.994 | 0.80 | nd | nd | nd | nd |
F2 | 0.959 | 0.969 | 0.992 | 0.981 | 0.74 | nd | nd | nd | nd |
F3 (MO 9) | 0.968 | 0.976 | 0.998 | 0.996 | 0.64 | 0.987 | 0.813 | 0.987 | 1.27 |
F4 | 0.928 | 0.939 | 0.985 | 0.977 | 0.72 | nd | nd | nd | nd |
F5 | 0.926 | 0.936 | 0.983 | 0.976 | 0.75 | nd | nd | nd | nd |
MO 1 | 0.968 | 0.977 | 0.993 | 0.987 | 0.83 | 0.984 | 0.835 | 0.853 | 1.19 |
MO 2 | 0.885 | 0.901 | 0.996 | 0.982 | 0.67 | 0.980 | 0.830 | 0.884 | 1.37 |
MO 4.5 | 0.958 | 0.935 | 0.998 | 0.996 | 0.99 | 0.985 | 0.843 | 0.680 | 1.33 |
GL 10 | 0.953 | 0.967 | 0.986 | 0.998 | 0.78 | 0.935 | 0.843 | 0.797 | 1.16 |
GL 20 | 0.947 | 0.957 | 0.981 | 0.976 | 0.83 | 0.935 | 0.843 | 0.792 | 1.15 |
OA 5 | 0.951 | 0.953 | 0.997 | 0.922 | 0.46 | 0.992 | 0.876 | 0.845 | 0.84 |
OA 10 | 0.862 | 0.864 | 0.983 | 0.952 | 0.55 | 0 | 0.883 | 0.810 | 0.99 |
PG 10 | 0.933 | 0.955 | 0.990 | 0.976 | 0.84 | 0.996 | 0.892 | 0.876 | 1.19 |
PG 20 | 0.873 | 0.895 | 0.993 | 0.966 | 0.95 | 0.969 | 0.806 | 0.880 | 1.25 |
PEG 7.5 | 0.966 | 0.959 | 0.999 | 0.996 | 0.69 | 0.986 | 0.842 | 0.882 | 1.30 |
PEG 15 | 0.961 | 0.982 | 0.998 | 0.979 | 0.79 | 0.979 | 0.865 | 0.831 | 1.44 |
Each value represents the mean (n = 3)
nd not determined, r 2 correlation coefficient of linear regression, MO monoolein, P407 poloxamer 407, GL glycerol, OA oleic acid, PG propylene glycol, PEG polyethylene glycol 400